Delivery Order SPE2DR25D2014-SPE2DR26FA0S2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,835.51 to AmerisourceBergen Drug Corp for 90 tablets of Livalo 2 mg, a pharmaceutical product used to manage cholesterol levels. The award was issued on July 14, 2025, with an ultimate completion date of July 15, 2025, and was competitively awarded without a set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $22,629.65 to AmerisourceBergen Drug Corp for the supply of Livalo 1 mg tablets (90-count) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is issued as a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $3,953.53 to AmerisourceBergen Drug Corp for the supply of Livalo 4 mg tablets (90-count units), with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order under a non-set-aside competitive procurement. The awardee, AmerisourceBergen Drug Corp, is a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, and will fulfill this order from its corporate office location in the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Livalo 1 mg tablets (90-count packages) with a ceiling value of $4,675.27. This competitive award, executed as a firm fixed-price delivery order with no set-aside designation, represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's Corporate Office location...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,336.06 for 90 tablets of Livalo 2 mg on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Livalo 2 mg tablets (90-count) with a ceiling value of $1,119.63. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of LIVALO 2 MG TABLET 90S. The contract has a ceiling value of $1,273.59 and runs through August 6, 2024. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
- Amerisourcebergen Drug Corp has been awarded a firm fixed price delivery order by the Defense Logistics Agency (DLA) Troop Support Medical for $2,720.25. The order is for 90 tablets of the generic cholesterol medication Livalo 1 mg, to be delivered by December 6, 2023 to DLA's facility in Conshohocken, Pennsylvania. As a prime contractor supporting DLA Troop Support Medical, Amerisourcebergen will supply pharmaceutical products and medical supplies for military treatment programs. No set-aside...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of LIVALO 2 MG TABLET 90S, a pharmaceutical product. The contract has a ceiling value of $2,977.16 and a completion date of August 14, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of LIVALO 1 MG TABLET 90S. The contract has a potential value of $1,313.12 and a completion date of February 21, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order contract, which is part of a larger indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 and...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FA0S2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,578.60 to AmerisourceBergen Drug Corp for 90-count tablets of Livalo 1 mg, a pharmaceutical product used in cholesterol management. This non-set-aside contract was competitively awarded on December 23, 2025, with an ultimate completion date of December 24, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order utilizes firm fixed pricing and operates under a child contract structure. This delivery order is issued under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a wide range of medications, vaccines, and medical supplies to support military healthcare programs and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 12/22/25 |